Company Overview:
Avidity Biosciences
RNA is pioneering RNA therapeutics with its Antibody Oligonucleotide Conjugates (AOC) platform, aiming at rare genetic diseases where no treatments exist—unlocking high unmet demand.
Financial Snapshot (Q2):
Revenue: $3.85M
Net loss: $157.31M (reflecting heavy early-stage R&D investment)
Valuation: P/S 529.67, P/B 9.27, signaling premium growth pricing by investors.
Technical View:
Stock has formed multiple bull flag patterns.
Breakout potential is strong after recent consolidation phase.
Investment Outlook:
Bullish above: $37.00–$38.00
Upside target: $70.00–$72.00, supported by pipeline innovation + bullish technical setup.
📢 RNA — premium biotech bet with rare-disease focus and breakout momentum.
#RNA #Biotech #Genomics #GrowthStocks #BullFlag #Breakout
Avidity Biosciences
RNA is pioneering RNA therapeutics with its Antibody Oligonucleotide Conjugates (AOC) platform, aiming at rare genetic diseases where no treatments exist—unlocking high unmet demand.Financial Snapshot (Q2):
Revenue: $3.85M
Net loss: $157.31M (reflecting heavy early-stage R&D investment)
Valuation: P/S 529.67, P/B 9.27, signaling premium growth pricing by investors.
Technical View:
Stock has formed multiple bull flag patterns.
Breakout potential is strong after recent consolidation phase.
Investment Outlook:
Bullish above: $37.00–$38.00
Upside target: $70.00–$72.00, supported by pipeline innovation + bullish technical setup.
📢 RNA — premium biotech bet with rare-disease focus and breakout momentum.
#RNA #Biotech #Genomics #GrowthStocks #BullFlag #Breakout
免责声明
这些信息和出版物并不意味着也不构成TradingView提供或认可的金融、投资、交易或其它类型的建议或背书。请在使用条款阅读更多信息。